Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:XLRN

Acceleron Pharma (XLRN) Stock Price, News & Analysis

Acceleron Pharma logo

About Acceleron Pharma Stock (NASDAQ:XLRN)

Advanced Chart

Key Stats

Today's Range
$178.75
$178.75
50-Day Range
$172.08
$179.68
52-Week Range
$108.82
$189.99
Volume
N/A
Average Volume
572,759 shs
Market Capitalization
$10.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive XLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter.

XLRN Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Acceleron Banks on Muons for Colder Fusion
ORBIMED CAPITAL GP II LLC's Net Worth
XLRN Historical Data
See More Headlines

XLRN Stock Analysis - Frequently Asked Questions

Acceleron Pharma Inc. (NASDAQ:XLRN) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.18. The company's quarterly revenue was up 51.6% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX).

Company Calendar

Last Earnings
11/04/2021
Today
7/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:XLRN
CIK
1280600
Employees
312
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$166.03 million
Net Margins
-226.01%
Pretax Margin
-225.99%
Return on Equity
-32.11%
Return on Assets
-29.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.14
Quick Ratio
12.14

Sales & Book Value

Annual Sales
$92.52 million
Price / Sales
118.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.74 per share
Price / Book
15.23

Miscellaneous

Outstanding Shares
61,156,000
Free Float
60,116,000
Market Cap
$10.93 billion
Optionable
Optionable
Beta
0.13

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:XLRN) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners